findmyKOL
Clinical trialNCT06007937Active, not recruitingPhase 1/PHASE2Interventional

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment9MetastaticNon Small Cell Lung CancerRecurrent
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Monmouth (all Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (all Protocol Activities)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (all Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering West Harrison (all Protocol Activities)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center (all Protocol Activities)

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (all Protocol Activities)

    Rockville Centre, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lorlatinib →Ramucirumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Aug 2023
Primary completion
17 Aug 2028
Completion
17 Aug 2028
Last update posted
13 Aug 2026
Registered enrollment
9
Registry id
NCT06007937
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.